Amyotrophic lateral sclerosis (ALS) is a heterogeneous group of incurable motor neuron diseases (MNDs) characterized by a selective loss of upper and lower motor neurons in the brain and spinal cord. Most cases of ALS are sporadic, while approximately 5–10% cases are familial. More than 16 causative genes for ALS/MNDs have been identified and their underlying pathogenesis, including oxidative stress, endoplasmic reticulum stress, excitotoxicity, mitochondrial dysfunction, neural inflammation, protein misfolding and accumulation, dysfunctional intracellular trafficking, abnormal RNA processing, and noncell-autonomous damage, has begun to emerge. It is currently believed that a complex interplay of multiple toxicity pathways is implicated in disease onset and progression. Among such mechanisms, ones that are associated with disturbances of protein homeostasis, the ubiquitin-proteasome system and autophagy, have recently been highlighted. Although it remains to be determined whether disease-associated protein aggregates have a toxic or protective role in the pathogenesis, the formation of them results from the imbalance between generation and degradation of misfolded proteins within neuronal cells. In this paper, we focus on the autophagy-lysosomal and endocytic degradation systems and implication of their dysfunction to the pathogenesis of ALS/MNDs. The autophagy-endolysosomal pathway could be a major target for the development of therapeutic agents for ALS/MNDs.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a heterogeneous group of inexorable neurodegenerative disorders characterized by a selective loss of upper and lower motor neurons in the brain and spinal cord [1, 2]. Most patients die of respiratory failure within 3–5 years. Although ALS is one of the best studied and a well-known form of motor neuron diseases (MNDs), the molecular pathogenesis of ALS is still unclear [1, 2]. To date, no effective therapeutic interventions to cure or even relieve symptoms are available [3].
Most cases of ALS are sporadic, while approximately 5–10% cases are familial. Recent advances in human genetics and genomics greatly facilitate the chromosomal mapping of disease loci, and the identification of causative genes and mutations predisposing to many familial forms of ALS/MNDs [1]. Thus far, more than 16 ALS causative genes including SOD1, ALS2, SETX, SPG11, FUS, VAPB, ANG, TARDBP, FIG4, OPTN, ATXN2, VCP, C9orf72, UBQLN2, SIGMAR1, and CHMP2B have been identified [1, 4] (http://neuromuscular.wustl.edu/index.html) (Table 1). The following characterizations of the disease-causing and -related gene products, in conjunction with the creation of animal models, have successfully unveiled the molecular basis underlying the pathogenesis of ALS/MNDs, such as oxidative stress, endoplasmic reticulum (ER) stress, excitotoxicity, mitochondrial dysfunction, neural inflammation, protein misfolding and accumulation, dysfunctional intracellular trafficking, abnormal RNA processing, and noncell-autonomous damage [4–11]. It is currently believed that a complex interplay of such multiple toxicity pathways, rather than a single independent mechanism, is implicated in the ALS/MND’s pathogenesis [4–6].
Genes associated with ALS and other neurodegenerative diseases.
Disease type
Locus
Gene
Protein
Inheritance*
Onset
Function
Mutation linked to other diseases
ALS1
21q22.11
SOD1
SOD1
D
Adult
Oxidative and ER stress response
ALS2
2q33.1
ALS2
ALS2/alsin
R
Juvenile
Trafficking and protein degradation
PLSJ, IAHSP
ALS3
18q21
—
—
D
Adult
—
ALS4
9q34.13
SETX
Senataxin
D
Juvenile
DNA damage response
AOA2
ALS5
15q21.1
SPG11
Spatacsin
R
Juvenile
—
SPG11
ALS6
16p11.2
FUS
FUS
D
Adult
DNA and RNA metabolism
ALS-FTD
ALS7
20p13
—
—
D
Adult
—
ALS8
20q13.32
VAPB
VAPB
D
Adult
ER and Golgi membrane trafficking
SMA4
ALS9
14q11.2
ANG
Angiogenin
D
Adult
Neuroprotection
PD or ALS-PD
ALS10
1p36.22
TARDBP
TDP-43
D, R, or S
Adult
DNA and RNA metabolism
ALS-FTD, FTD
ALS11
6q21
FIG4
FIG4
D or S
Adult
PI (3,5) P2 regulation
CMT4J
ALS12
10p13
OPTN
Optineurin
D or R
Adult
NFkB regulation
GLC1E
ALS13
12q24.12
ATXN2
Ataxin-2
D
Adult
Gene regulation
SCA2
ALS14
9p13.3-p12
VCP
VCP or p97
D
Adult
Protein degradation
IBMPFD
ALS15
Xp11.21
UNQLN2
Ubiquilin-2
D
Adult
Protein degradation
ALS-FTD
ALS16
9p13.3
SIGMAR1
SIGMAR1
R
Juvenile
ER chaperon
ALS-FTD1
9q21-q22
—
—
D or S
Adult
—
ALS-FTD2
9p21.2
C9orf72
C9ORF72
D or S
Adult
—
FTD
ALS-FTD3
3p11.2
CHMP2B
CHMP2B
D
Adult
Trafficking and protein degradation
DHN-7B
2p13.1
DCTN1
Dynactin-1
D
Adult
Trafficking
Perry syndrome
CMT2B
3q21.3
RAB7
Rab7
D
Adult
Trafficking and protein degradation
CMT2O
14q32.31
DYNC1H1
Dynein
D
Adult
Trafficking
SMA-LED and MRD13
ALS**
5q35.3
SQSTM1
Sequestosome or p62
?
Adult
Protein degradation
PDB
*Inheritance (D: dominant, R: recessive, and S: sporadic). FTD: Frontotemporal dementia, DHN: distal hereditary motor neuronopathy, CMT: Charcot-Marie-Tooth disease, PDB: Paget disease of bone, PLSJ: primary lateral sclerosis juvenile, IAHSP: infantile-onset ascending hereditary spastic paralysis, AOA: ataxia-ocular apraxia-2, SPG: spastic paraplegia, SMA: spinal muscular atrophy, PD: Parkinson's disease, GLC1E: glaucoma 1, open angle, E, SCA2: spinocerebellar ataxia-2, IBMPFD: inclusion body myopathy with dementia and Paget disease of bone, SMA-LED: spinal muscular atrophy with lower limb predominance, and MRD13: mental retardation, autosomal dominant 13. **ALS: Fecoto et al. reported several novel SQSTM1 mutations in patients with ALS and predicted 8 of 9 missense variants behave like a pathogenic mutant by in silico analysis [64].
Among these pathogenic mechanisms, ones that are associated with disturbances of protein homeostasis have been highlighted, as the accumulation of insoluble protein aggregates is the cardinal pathological feature for ALS and other neurodegenerative diseases [12]. Although it remains to be determined as to whether such protein aggregates have a toxic or protective role in the pathogenesis of ALS/MNDs, it is conceivable that the formation of them results from the imbalance between generation and degradation of misfolded proteins within neuronal cells. In eukaryotes, there are two main degradation systems for cytoplasmic proteins, that is, the ubiquitin-proteasome system (UPS) and autophagy. The UPS is mainly involved in selective clearance for short-lived proteins [13], while autophagy is the mechanism by which the long-lived as well as misfolded proteins can be removed by the endolysosomal system [14, 15]. It is also noted that the involvement of endocytosis and vesicle trafficking in the regulation of protein homeostasis and degradation have recently emerged [10, 16–18].
In this paper, we aim to give a comprehensive view on the autophagy-endolysosomal system and implication of its dysfunction to the pathogenesis of ALS/MNDs. Excellent review articles specialized on the role of the UPS in ALS/MNDs can be found elsewhere [13, 19].
2. The Autophagy-Endolysosomal System2.1. Autophagic Pathways
Autophagy is an evolutionally conserved lysosomal degradation system that is tightly linked to a wide variety of physiological processes such as protein homeostasis, removal of pathogens, and antigen presentation. There are at least three forms of autophagic pathways; macroautophagy, microautophagy, and chaperon-mediated autophagy, among which macroautophagy, hereafter referred to as “autophagy”, plays a crucial role in the removal of cytoplasmic long-lived as well as misfolded proteins [14, 20–23]. Autophagy comprises three sequential steps; autophagosome formation, maturation, and degradation within lysosomes, through which entrapped cargo molecules within autophagosomes can be degraded and reutilized for the synthesis of newer cellular components.
These multiple steps of autophagy are highly orchestrated by a common group of proteins called ATG (autophagy-related), such as Atg5 and Atg7 [14], and Rab GTPases, a large family of small G proteins [24]. While most autophagic pathways are Atg5/Atg7-dependent, an Atg5/Atg7-independent but Rab9-dependent alternative autophagic pathway has recently been found in mammals [25]. Although autophagy is highly upregulated under stress conditions such as nutritional starvation [14] and exercise [26] (BCL2/Beclin-1-dependent inducible autophagy), several lines of evidence support the existence of basal or constitutive autophagy (BCL2/Beclin-1-independent basal autophagy) in most cell types including neuronal and muscle cells [26–30]. In fact, despite that starvation does not induce autophagy in the brain [31], either Atg5 or Atg7 deficiency in neurons results in the accumulation of misfolded proteins and neurodegeneration [29, 30], indicating that basal autophagy has a crucial role in the central nervous system (CNS).
Whichever autophagic mechanisms except Atg5/Atg7-independent alternative [25] are involved, their activation can be monitored by the level and distribution of two autophagy-associated proteins. One is microtubule-associated protein 1 light chain 3 (LC3), a yeast Atg8 homolog, whose lipidated forms (LC3-II) are highly enriched onto autophagosomal membranes [32] (Figure 1). The other is p62 (a.k.a. sequestosome 1/SQSTM1), an adaptor molecule for selective autophagosomal degradation of ubiquitinated targets, which directly binds to LC3, thereby promoting the recruitment and engulfment of cargos to autophagosomes [33–35] (Figure 1).
Endocytic trafficking and the autophagy-endolysosomal system in neurons.
2.2. Endocytic Pathways
Endocytosis is an evolutionally conserved cellular process involving the internalization of a wide variety of molecules from the surface of cells. There are at least four distinct well-recognized endocytic pathways in eukaryotes: phagocytosis, macropinocytosis, clathrin-mediated endocytosis (CME), and caveola-mediated endocytosis [36–38] (Figure 1). In addition, several other uncharacterized clathrin- and caveolin-independent pathways exist [38]. Each endocytic pathway mediates the transport of specific cargo molecules and delivers them to the correct destinations within cells. It is highly appreciated that most internalized vesicles and/or vacuoles containing specific cargos mature to or fuse with early endosomes before the cargos are delivered to their end destinations [38], and that a variety of the distinctive Rab GTPases, such as Rab5 and Rab7, control endocytosis and vesicle trafficking as well as cargo transportation [39]. Interestingly, a recent study has demonstrated that certain types of endocytosis (macropinocytosis) and autophagy are oppositely regulated by a phospholipid binding protein Annexin A5, suggesting a coordinated cross-talk between endocytic and autophagic pathways [40].
2.3. Maturation of Autophagosomes, Macropinosomes, and Endosomes
Nascent autophagosomes undergo a stepwise maturation, resulting in the creation of amphisomes and autolysosomes by fusion with multiple endocytic compartments, such as early endosomes, multivesicular bodies (MVBs), late endosomes, and lysosomes [41, 42]. Amphisomes, an intermediate hybrid vesicular compartment, contain both autophagosomal and endosomal contents, while autolysosomes are formed either from amphisomes or directly from autophagosomes by fusion with lysosomes [41] (Figure 1). Notably, not only the internalized vacuoles such as macropinosomes that are generated through macropinocytosis but also early endosomes themselves sequentially mature into MVBs, late endosomes, and lysosomes [15] (Figure 1). Further, it has recently been shown that fusion of autophagosomes with early endosomes is required for autophagy [43]. These findings strongly support an intimate crosstalk between autophagic and endocytic pathways particularly in their maturation steps.
Elaborate molecular mechanisms regulating the maturation of intracellular vesicular/vacuolar compartments have recently begun to emerge. Those include Rab-switching, phosphatidylinositol (PI) conversion, endosomal sorting complex required for transport (ESCRT) machinery, as well as lumenal acidification, as reviewed in detail elsewhere [15, 41, 42, 44]. Among the systems, the sequential action of the small GTPases Rab5 and Rab7, that is, the Ra5-Rab7 switching, plays a central role in the early step of the endosome maturation; early to late endosomes [15, 45, 46]. Further, it has been reported that the sequential reaction of Rab5-Rab21-Rab7 plays a pivotal role in macropinocytosis and the macropinosome maturation [47]. PI conversions mediated by VPS34 and PIKfyve also tightly link to the maturation from Rab5- to Rab7-positive endosomes [15]. Of particular, the Class III phosphatidylinositol-3 kinase (PI3K) complexes containing p150, Beclin-1, VPS34, and UVRAG positively regulate the maturation of both autophagosomes and endosomes [15, 42, 48]. On the other hand, the ESCRT complexes play a major role in the later step of the autophagosome, amphisome, and endosome maturation [49]. Moreover, histone deacetylase-6 (HDAC6), a ubiquitin-binding deacetylase acting as a central component of basal autophagy, selectively targets the ubiquitinated proteins to autophagosomes [35], and controls the autophagosome maturation rather than the autophagosome formation [50]. Despite of such recent progress, molecular mechanisms underlying coordinated regulation of multiple maturation steps by these factors are still incompletely understood.
Since autophagosomes as well as endosomes are motile within cells [51, 52], it is reasonable that their movements are linked to their maturation stages, particularly in differentiated neuronal cells. Indeed, Rab5 and Rab7 act in a coordinated manner in controlling the early stage of maturation and the axonal retrograde transport of vesicles in motor neurons [52]. Further, Snapin, a neuronal SNARE-binding protein acting as an adaptor linking late endosomes to the dynein complex, plays key roles not only in dynein-mediated retrograde transport but also in late endosomal-lysosomal maturation in neurons [53]. Most recently, it has also been shown that autophagosomes are formed and fuse with late endosomes and/or immature lysosomes distally, and their maturation progresses during transport along the axons in primary dorsal root ganglion (DRG) neurons [54].
2.4. Lysosomal Degradation
The final step of the autophagy-endolysosomal system is degradation of cargo molecules within lysosomes. Two classes of proteins; lysosomal acid hydrolases and lysosomal membrane proteins (LMPs), play essential roles in degradation of cargos in lysosomes. Lysosomal acid hydrolases such as cathepsins are involved not only in bulk degradation of substrates (cargos) but also in other physiological processes such as antigen processing. On the other hand, LMPs have a wide variety of functions including lumenal acidification, import of cytosolic proteins, and transport of degraded materials to cytosol. Excellent review article specialized on lysosome biogenesis is available elsewhere [55].
Lysosomal positioning is dynamically regulated by nutritional conditions, in which a starvation induces preferential relocalization of lysosomes from cell peripheries to the juxtanuclear regions close to the microtubule-organizing center (MTOC), thereby regulating the autophagic flux in cells [56]. In neurons, bidirectional movements of lysosomes within axons are observed [57, 58]. While autophagosomes and endosomes are also bidirectionally moved in the distal axons [54], they are rather exclusively transported in a retrograde direction upon fusion with lysosomal-associated membrane protein 1 (LAMP-1)-positive late endosomes and/or immature lysosomes [51, 52, 54, 57]. Further, fully matured lysosomes containing active lysosomal hydrolases are confined to the proximal region of axons or the cell body [54, 57]. Thus, autophagosomes and endosomes formed in axons must be transported to the cell body for a complete digestion of their cargos [27] (Figure 1). Recent evidence showing that defective Snapin-dynein-mediated retrograde transport in neurons results in the aberrant accumulation of immature lysosomes and impaired lysosomal degradation [53] supports this notion. Taken together, lysosomal degradation of either engulfed or internalized cargos in neurons might be strictly dependent on retrograde transport and late endosomal-lysosomal trafficking [51, 53, 58].
3. Dysfunction of the Autophagy-Endolysosomal System in Motor Neuron Diseases
Growing evidence supports a role of the autophagy-endolysosomal pathway in the pathogenesis of ALS/MNDs. Indeed, the accumulation of autophagosomes were observed in the spinal cord of sporadic ALS patients [59], indicating autophagic dysfunction in ALS. Autophagic dysfunction includes defects in the initiation (formation of autophagosomes) and/or maturation stages of autophagic processes, as well as imbalance between them, resulting in aberrant accumulation of misfolded and/or aggregated proteins within cells. Such pathological conditions disturb neuronal homeostasis, leading to neurodegeneration. In this section, we focus on causative and/or associated genes for ALS/MNDs, whose gene products functionally link to the autophagy-endolysosomal system; including SOD1 [60], FIG4 [61], VCP [62], CHMP2B [63], SQSTM1 [64], DCTN1 [65], DYNC1H1 [66], and RAB7A [67] (Table 1). We describe ALS2 [68, 69] and its product ALS2/alsin, an emerging regulator for autophagy-endolysosomal system [70, 71], in a separate section (see Section 4). Other ALS/MND causative genes, such as TARDBP [72], OPTN [73], and UBQLN2 [74], which are also associated with protein degradation, are described in detail elsewhere [4, 75].
3.1. Superoxide Dismutase 1 (SOD1): ALS1
Mutations in SOD1 that encodes superoxide dismutase 1 (SOD1) account for an approximately 20% of familial ALS cases [1]. It is currently believed that the SOD1-mediated dismutase enzymatic activity is not a major determinant for the phenotypic modification in ALS, since there is no correlation between disease severities and the SOD1 dismutase activities [76, 77]. Rather, the propensity for the aggregate formation associated with mutant SOD1 proteins, that is, gain of toxic function, might be related to the phenotypic expression of disease [78]. Recently, it has been reported that the normal as well as mutant SOD1 proteins are degraded both by the UPS and the autophagy-endolysosomal system [70, 79]. SOD1 mutants can be recognized by p62 in an ubiquitin-independent manner and targeted for degradation through the autophagy-endolysosomal pathway [80, 81]. Importantly, progressive enhancement of autophagy and/or decrease of autophagic flux are detected in a mutant SOD1 (SOD1G93A)-expressing ALS mouse model [82–84]. Most recently, heat-shook protein 70 (Hsp70) and Bcl2-associated athanogene 3 (BAG3) mediate the ubiquitination-independent autophagic degradation of misfolded proteins including SOD1 mutants [85]. It is also noted that SOD1 mutants directly bind to the retrograde motor protein complex, thereby disturbing axonal transport [86–88] (see Section 3.6). Taken together, it is conceivable that increased accumulation of SOD1 mutants as disease progresses disturb the autophagy-endolysosomal system.
3.2. Phospholipid Phosphatase Fig4: ALS11
Mutations in FIG4 account for a form of autosomal recessive Charcot-Marie-Tooth type 4J (CMT4J) [89]. Interestingly, an approximately 2% of patients with ALS and primary lateral sclerosis (PLS) carry heterozygous deleterious mutations (nonsynonymous variants) in FIG4 [61], indicating that FIG4 is implicated in the pathogenesis of both peripheral neuropathy and ALS/MNDs. FIG4 encodes a phosphoinositide 5-phosphatase, Fig4, that regulates the intracellular level of phosphatidylinositol-3,5,-bisphosphate (PI(3,5)P2). It has been shown that mutation in FIG4 results in a significant reduction of the PI(3,5)P2 level in cultured cells [88]. Further, mice lacking Fig4, exhibit the accumulation of LC3-II, p62, and LAMP-2 in neurons and astrocytes, and die earlier than wild-type litters [90]. Thus, deregulation of the autophagy-endolysosomal system, namely the later stage of autophagosome and/or endosome maturation, might be associated with the pathogenesis of FIG4-linked ALS/MNDs (Figure 2).
ALS-linked mutations in the genes, whose protein products are associated with autophagy-endolysosomal system and/or endocytic trafficking, underlie the pathogenesis of ALS and related motor neuron diseases.
3.3. Valosin-Containing Protein (VCP/p97): ALS14
Mutations in VCP have previously been identified in patients with inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD) [91]. Recently, exome sequencing reveals VCP mutations as a cause of familial ALS, accounting for 1-2% of familial ALS [62]. VCP encodes valosin-containing protein (VCP/p97) that belongs to the AAA+ (ATPases associated with various activities) protein family, being implicated in multiple cellular processes including the UPS [92, 93]. A recent study has shown that VCP/p97 regulates endolysosomal sorting of endocytosed ubiquitinated cargos such as caveolin-1 [94]. Further, loss of VCP/p97 accelerates the accumulation of autophagosomes [95], and expression of IBMPFD-linked mutants results in the impaired maturation of autolysosomes with accompanying the cytoplasmic accumulation of TAR DNA-binding protein (TDP-43), a causative gene product for ALS10 and a major constituent of ALS-linked cytoplasmic inclusions [72, 95–97]. Thus, VCP/p97 might play essential roles not only in the maturation of autophagosomes and endolysosomes, but also in the regulation of intracellular dynamics of TDP-43.
3.4. Charged Multivesicular Body Protein 2B (CHMP2B): ALS-FTD3
Mutations in CHMP2B have been identified in patients with FTD and ALS-FTD [63, 98]. CHMP2B encodes charged multivesicular body protein 2B (CHMP2B), a component of the ESCRT-III complex. The ESCRT complexes are known to play important roles in MVB biogenesis and autophagosomal-endolysosomal maturation [99]. Either functional loss of ESCRT-III or ectopic expression of disease-linked CHMP2B mutants causes the accumulation of LC3-positive autophagosomes accompanying protein aggregates containing ubiquitinated proteins and p62 [49], and results in dendritic retraction prior to neurodegeneration [100]. Interestingly, ESCRT-depleted cells also exhibit the accumulation of TDP-43 positive cytoplasmic inclusions [49]. These results indicate that deregulation of MVB biogenesis and autophagy is implicated in the pathogenesis of CHMP2B-linked FTD and ALS-FTD (Figure 2).
3.5. Sequestosome 1 (SQSTM1/p62)
SQSTM1 encodes SQSTM1/p62 that was originally isolated as an interacting protein for the atypical protein kinases (aPKCs) [101]. It has been shown that p62 acts as an adaptor and/or scaffold protein that regulates not only the NF-κB activation through the binding with aPKCs but also the selective-autophagy via association with ubiquitinated misfolded proteins [102–104]. Further, accumulation of p62 by defective autophagy causes competitive inhibition of the oxidative-stress responsive transcription factor Nrf2-Keap1 interaction, resulting in activation of Nrf2 and its target antioxidative stress genes [105]. Conversely, genetic inactivation of Sqstm1 in mice results in the accumulation of hyperphosphorylated tau and neurodegeneration [106]. Although mutations in SQSTM1 have originally been identified in patients with Paget disease of bone (PDB) [107], a recent study has revealed several missense variants in SQSTM1 in familial as well as sporadic ALS [64]. It is notable that abundant p62-positive inclusions in the brain are a typical pathological feature of ALS or ALS-FTD associated with hexanucleotide repeat expansion in C9orf72 [108, 109]. Considering the facts that two independent genes linking to forms of Paget disease of bone; VCP for IBMPFD and SQSTM1 for PDB, are also associated with ALS and/or ALS-FTD, and that both VCP and p62 are key regulators for the autophagy-endolysosomal system, dysregulation of such VCP/p62-associated common pathological pathways might account for these seemingly different diseases.
3.6. Dynein/Dynactin Complex
Mutation in DCTN1 encoding the p150 subunit of the transporter protein dynactin has been identified in autosomal dominant form of lower MNDs [65]. Dynactin functions as an adaptor between dynein and various cargos, thereby regulating the efficiency of dynein motor [11]. It has also been shown that expansion of polyglutamine-tract in androgen receptor, which causes a form of motor neuron disease; spinal and bulbar muscular atrophy (SBMA), results in polyglutamine-dependent transcriptional dysregulation of dynactin [110]. Moreover, overexpression of dynamitin (p50) subunit of dynactin, which causes a dissociation of the dynactin complex, thereby interfering the dynein/dynactin-dependent retrograde transport, causes MND in mice [111]. On the other hand, several studies identify mutations in the component of dynein motor complex itself. Exome sequencing reveals the mutation in DYNC1H1 encoding cytoplasmic dynein heavy chain in patients with dominant form of axonal CMT [66]. Mutations in a mouse homolog Dync1h1 have also been identified, resulting in progressive motor neuron degeneration in mice [86]. It has been demonstrated that a mutant SOD1-expressing ALS mouse model carrying dynein mutation shows a defective axonal transport [86, 87]. Further, SOD1 mutants preferentially interact with the dynein complex, disturbing their functions [88]. Interestingly, decreased dynein function impairs the autophagy-dependent clearance of misfolded protein aggregates in parallel with the increased level of LC3-II-positive autophagosomes [112]. Collectively, defects in dynein/dynactin-mediated retrograde axonal transport are involved in etiology of ALS/MNDs [11] (Figures 1 and 2).
3.7. Small GTPase Rab7
Charcot-Marie-Tooth type 2B (CMT2B) is an autosomal-dominant peripheral neuropathy caused by the missense mutations in RAB7A [67]. These mutations cause the constitutive activation of its encoding protein Rab7 [113], a regulator of maturation of autophagosomes, amphisomes, and late endosomes in cells [114–116] (Figures 1 and 2). Although the molecular mechanism by which dysfunction in a ubiquitously expressed Rab7 affects only sensory and/or motor neurons remains unclear, recent studies have demonstrated that these CMT2B-associated Rab7 mutants exhibit a persistent elevation of endosome-mediated nerve growth factor (NGF) signaling [117], and inhibit neurite outgrowth in cultured neuronal cells [118].
4. ALS2/alsin: A Regulator of Autophagy-Endolysosomal Protein Degradation
Loss of function mutations in the ALS2 gene accounts for juvenile recessive amyotrophic lateral sclerosis (ALS2), juvenile primary lateral sclerosis (JPLS), and infantile-onset ascending hereditary spastic paralysis (IAHSP) [68, 69, 119, 120]. The ALS2 gene encodes a 184 kDa protein of 1657 amino acids, ALS2 or alsin, comprising three predicted guanine nucleotide exchange factor (GEF) domains: the N-terminal RCC1-like domain (RLD), the central Dbl homology and pleckstrin homology (DH/PH) domain, and the C-terminal vacuolar protein sorting 9 (VPS9) domain [68]. Indeed, it has been shown that ALS2 acts as a GEF for Rab5 [120–122], and regulates endosome fusion and trafficking by activating Rab5 [120, 121, 123] (Figure 1). ALS2 is also involved in Rac1-activated macropinocytosis and the following macropinosome trafficking and fusion [124, 125]. In particular, fusion between early endosomes and macropinosomes is, at least in part, regulated by ALS2 in an ALS2-associated Rab5 GEF activity-dependent manner [124]. Further, ALS2 plays some modulatory roles in axonal outgrowth in neuronal cells [125, 126], and in cytoprotection from oxidative stress-induced insults [127–130].
Recently, we have demonstrated that activated Rac1 interacts with ALS2 and induces the relocalization of ALS2 from cytoplasm to membranous compartments; for example, membrane ruffle, macropinosome, and endosome [124]. This Rac1-mediated relocalization of ALS2 is required for the ALS2-mediated Rab5 activation on the membranous compartments [71, 124]. It is noted that ALS2 is also colocalized with LC3/p62-positive autophagosomes and/or amphisomes [70, 71]. Conversely, pathogenic missense ALS2 mutants fail to be localized to such vesicular compartments, and lose the competence to enhance the formation of amphisomes [71], indicating that the Rac1-induced relocalization of ALS2 might be crucial to exert the ALS2-associated function linking to the autophagy-endolysosomal degradative pathway. Indeed, loss of ALS2 results in a slower degradation of endocytosed epidermal growth factor (EGF) in mouse embryonic fibroblasts [131]. Further, an ALS2-deficient SOD1H46R-expressing ALS mouse model exhibits the aberrant accumulation of autophagosomes and vesicular compartments in axons, delayed protein degradation by the autophagy-endolysosomal system, accelerated neurodegeneration, and earlier death [70]. Although the exact physiological function of ALS2 remains to be clarified, it is currently believed that ALS2 plays an important role in trafficking and maturation of several distinct vesicular compartments, including macropinosome, endosome, and autophagosome, and is implicated in the autophagy-endolysosomal degradative pathways (Figure 2).
5. Conclusions and Perspectives
Thus far, a large number of successful therapeutic interventions in preclinical animal studies have failed to translate into human clinical applications in ALS/MNDs. Even in such a discouraging situation, enormous efforts have continuously been made towards defining the molecular pathogenesis of these devastating diseases. The autophagy-endolysosomal system is among the underlying mechanisms, whose dysfunction is tightly associated with a variety of neurodegenerative diseases. It plays a pivotal role not only in ALS/MNDs as discussed in this paper, but also in other neurodegenerative diseases including Alzheimer’s disease [57], Parkinson’s disease [132], and Huntington’s disease [133, 134]. Thus, the autophagy-endolysosomal pathway could be a major target for the development of novel therapeutic agents for neurodegenerative diseases [135]. Indeed, the induction of autophagy by lithium administration results in a reduced level of aggregated proteins and extends lifespan in a SOD1G93A-expressing ALS mouse model [136]. However, a recent preclinical animal study has demonstrated that the treatment with rapamycin, an another inducer of autophagy, rather causes the accumulation of p62, more severe mitochondrial impairment, higher Bax levels, and greater caspase-3 activation, thereby augmenting motor neuron degeneration in a same ALS mouse model [137]. These conflicting results imply that the simple pharmacological induction of autophagy cannot be always beneficial in vivo. As such, our understanding of the intricate autophagy-endolysosomal system and its functional linking to other physiological systems in the CNS is still incomplete. Future studies, which could uncover the molecular mechanisms of a selective neurodegeneration in greater detail, will be required for the development of proper and effective therapeutic agents for the treatment of ALS/MNDs and other neurodegenerative diseases.
Acknowledgments
A. Otomo is supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS). S. Hadano is supported by Research and Study Project of Tokai University Educational System General Research Organization, a Grant-in-Aid for Scientific Research from JSPS, Daiichi-Sankyo Foundation of Life Science, and Japan-China Medical Association.
AndersenP. M.Al-ChalabiA.Clinical genetics of amyotrophic lateral sclerosis: what do we really know?20117116036152-s2.0-8075513337010.1038/nrneurol.2011.150HardimanO.van den BergL. H.KiernanM. C.Clinical diagnosis and management of amyotrophic lateral sclerosis20117116396492-s2.0-8075512821310.1038/nrneurol.2011.153GordonP. H.MeiningerV.How can we improve clinical trials in amyotrophic lateral sclerosis?20117116506542-s2.0-8075518992110.1038/nrneurol.2011.147FerraiuoloL.KirbyJ.GriersonA. J.SendtnerM.ShawP. J.Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis20117116166302-s2.0-8075516310210.1038/nrneurol.2011.152SwarupV.JulienJ. P.ALS pathogenesis: recent insights from genetics and mouse models20113523633692-s2.0-7995290057210.1016/j.pnpbp.2010.08.006PasinelliP.BrownR. H.Molecular biology of amyotrophic lateral sclerosis: insights from genetics2006797107232-s2.0-3374760532010.1038/nrn1971BarberS. C.MeadR. J.ShawP. J.Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target2006176211-12105110672-s2.0-3375100351810.1016/j.bbadis.2006.03.008BoilléeS.VeldeC. VClevelandD.ALS: a disease of motor neurons and their nonneuronal neighbors200652139592-s2.0-3374905680910.1016/j.neuron.2006.09.018KwakS.WeissJ. H.Calcium-permeable AMPA channels in neurodegenerative disease and ischemia20061632812872-s2.0-3374546079510.1016/j.conb.2006.05.004NassifM.MatusS.CastilloK.HetzC.Amyotrophic lateral sclerosis pathogenesis: a journey through the secretory pathway20101312195519892-s2.0-7814933931010.1089/ars.2009.2991StrömA. L.GalJ.ShiP.KasarskisE. J.HaywardL. J.ZhuH.Retrograde axonal transport and motor neuron disease200810624955052-s2.0-5084908326410.1111/j.1471-4159.2008.05393.xPolymenidouM.ClevelandD. W.The seeds of neurodegeneration: prion-like spreading in ALS201114734985082-s2.0-8015515784710.1016/j.cell.2011.10.011TaiH. C.SchumanE. M.Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction20089118268382-s2.0-5424915832410.1038/nrn2499MizushimaN.Autophagy: process and function20072122286128732-s2.0-3624902572310.1101/gad.1599207HuotariJ.HeleniusA.Endosome maturation20113017348135002-s2.0-8005223338910.1038/emboj.2011.286AgolaJ.JimP.WardH.BasurayS.Wandinger-NessA.Rab GTPases as regulators of endocytosis, targets of disease and therapeutic opportunitiesClinical Genetics. In pressYueZ.FriedmanL.KomatsuM.TanakaK.The cellular pathways of neuronal autophagy and their implication in neurodegenerative diseases200917939149615072-s2.0-6934909090710.1016/j.bbamcr.2009.01.016YamamotoA.SimonsenA.The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration201143117282-s2.0-7995594985810.1016/j.nbd.2010.08.015BendottiC.MarinoM.CheroniC.FontanaE.CrippaV.PolettiA.De BiasiS.Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response20129721011262-s2.0-8486068374910.1016/j.pneurobio.2011.10.001LevineB.KroemerG.Autophagy in the pathogenesis of disease2008132127422-s2.0-3764900523410.1016/j.cell.2007.12.018LongattiA.ToozeS. A.Vesicular trafficking and autophagosome formation20091679569652-s2.0-6754913990810.1038/cdd.2009.39MizushimaN.LevineB.CuervoA. M.KlionskyD. J.Autophagy fights disease through cellular self-digestion20084517182106910752-s2.0-3984910933810.1038/nature06639MizushimaN.KomatsuM.Autophagy: renovation of cells and tissues201114747287412-s2.0-8105514478410.1016/j.cell.2011.10.026ChuaC. E. L.GanB. Q.TangB. L.Involvement of members of the Rab family and related small GTPases in autophagosome formation and maturation20116820334933582-s2.0-8005475817610.1007/s00018-011-0748-9NishidaY.ArakawaS.FujitaniK.YamaguchiH.MizutaT.KanasekiT.KomatsuM.OtsuK.TsujimotoY.ShimizuS.Discovery of Atg5/Atg7-independent alternative macroautophagy200946172646546582-s2.0-7034968740510.1038/nature08455HeC.BassikM. C.MoresiV.SunK.WeiY.ZouZ.AnZ.LohJ.FisherJ.SunQ.KorsmeyerS.PackerM.MayH. I.HillJ. A.VirginH. W.GilpinC.XiaoG.Bassel-DubyR.SchererP. E.LevineB.Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis201248173825115152-s2.0-8485621210910.1038/nature10758KomatsuM.UenoT.WaguriS.UchiyamaY.KominamiE.TanakaK.Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons20071458878942-s2.0-3424739871910.1038/sj.cdd.4402120BolandB.KumarA.LeeS.PlattF. M.WegielJ.YuW. H.NixonR. A.Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease20082827692669372-s2.0-4904909656210.1523/JNEUROSCI.0800-08.2008HaraT.NakamuraK.MatsuiM.YamamotoA.NakaharaY.Suzuki-MigishimaR.YokoyamaM.MishimaK.SaitoI.OkanoH.MizushimaN.Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice200644170958858892-s2.0-3374519280210.1038/nature04724KomatsuM.WaguriS.ChibaT.MurataS.IwataJ. I.TanidaI.UenoT.KoikeM.UchiyamaY.KominamiE.TanakaK.Loss of autophagy in the central nervous system causes neurodegeneration in mice200644170958808842-s2.0-3364680030610.1038/nature04723MizushimaN.YamamotoA.MatsuiM.YoshimoriT.OhsumiY.In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker2004153110111112-s2.0-154228381210.1091/mbc.E03-09-0704RubinszteinD. C.CuervoA. M.RavikumarB.SarkarS.KorolchukV.KaushikS.KlionskyD. J.In search of an ‘autophagomometer’2009555855892-s2.0-6765022247410.4161/auto.5.5.8823IchimuraY.KumanomidouT.SouY. S.MizushimaT.EzakiJ.UenoT.KominamiE.YamaneT.TanakaK.KomatsuM.Structural basis for sorting mechanism of p62 in selective autophagy20082833322847228572-s2.0-5304910330810.1074/jbc.M802182200BjørkøyG.LamarkT.PankivS.ØvervatnA.BrechA.JohansenT.Chapter 12 monitoring autophagic degradation of p62/SQSTM120094521811972-s2.0-5924910596410.1016/S0076-6879(08)03612-4KirkinV.McEwanD. G.NovakI.DikicI.A role for ubiquitin in selective autophagy20093432592692-s2.0-6554914220410.1016/j.molcel.2009.04.026BowenS.AtehD. D.DeinhardtK.BirdM. M.PriceK. M.BakerC. S.RobsonJ. C.SwashM.ShamsuddinW.KawarS.El-TawilT.RoosJ.HoyleA.NickolsC. D.KnowlesC. H.PullenA. H.LuthertP. J.WellerR. O.HafezparastM.FranklinR. J. M.ReveszT.KingR. H. M.BerninghausenO.FisherE. M. C.SchiavoG.MartinJ. E.The phagocytic capacity of neurones20072510294729552-s2.0-3424998472110.1111/j.1460-9568.2007.05554.xMcMahonH. T.BoucrotE.Molecular mechanism and physiological functions of clathrin-mediated endocytosis20111285175332-s2.0-7996072032010.1038/nrm3151MayorS.PaganoR. E.Pathways of clathrin-independent endocytosis2007886036122-s2.0-3454711445610.1038/nrm2216StenmarkH.Rab GTPases as coordinators of vesicle traffic20091085135252-s2.0-6804910510110.1038/nrm2728GhislatG.AguadoC.KnechtE.Annexin A5 stimulates autophagy and inhibits endocytosis20121251921072-s2.0-8485814525810.1242/jcs.086728FaderC. M.ColomboM. I.Autophagy and multivesicular bodies: two closely related partners200916170782-s2.0-5764919540010.1038/cdd.2008.168SimonsenA.ToozeS. A.Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes200918667737822-s2.0-7034991980410.1083/jcb.200907014RaziM.ChanE. Y. W.ToozeS. A.Early endosomes and endosomal coatomer are required for Autophagy200918523053212-s2.0-6534915517410.1083/jcb.200810098NodaT.FujitaN.YoshimoriT.The late stages of autophagy: How does the end begin?20091679849902-s2.0-6754913252710.1038/cdd.2009.54RojasR.van VlijmenT.MardonesG. A.PrabhuY.RojasA. L.MohammedS.HeckA. J. R.RaposoG.Van Der SluijsP.BonifacinoJ. S.Regulation of retromer recruitment to endosomes by sequential action of Rab5 and Rab7200818335135262-s2.0-5614911294210.1083/jcb.200804048PoteryaevD.DattaS.AckemaK.ZerialM.SpangA.Identification of the switch in early-to-late endosome transition201014134975082-s2.0-7795191836210.1016/j.cell.2010.03.011EgamiY.ArakiN.Dynamic changes in the spatiotemporal localization of Rab21 in live RAW264 cells during macropinocytosis2009482-s2.0-6924915697510.1371/journal.pone.0006689e6689MatsunagaK.SaitohT.TabataK.OmoriH.SatohT.KurotoriN.MaejimaI.Shirahama-NodaK.IchimuraT.IsobeT.AkiraS.NodaT.YoshimoriT.Two beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages20091143853962-s2.0-6404908675810.1038/ncb1846FilimonenkoM.StuffersS.RaiborgC.YamamotoA.MalerødL.FisherE. M. C.IsaacsA.BrechA.StenmarkH.SimonsenA.Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease200717934855002-s2.0-3594898332810.1083/jcb.200702115LeeJ. Y.KogaH.KawaguchiY.TangW.WongE.GaoY. S.PandeyU. B.KaushikS.TresseE.LuJ.TaylorJ. P.CuervoA. M.YaoT. P.HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy20102959699802-s2.0-7764933712210.1038/emboj.2009.405KatsumataK.NishiyamaJ.InoueT.MizushimaN.TakedaJ.YuzakiM.Dynein- and activity-dependent retrograde transport of autophagosomes in neuronal axons2010633783852-s2.0-7795369305110.4161/auto.6.3.11262DeinhardtK.SalinasS.VerasteguiC.WatsonR.WorthD.HanrahanS.BucciC.SchiavoG.Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway20065222933052-s2.0-3374962037310.1016/j.neuron.2006.08.018CaiQ.LuL.TianJ. H.ZhuY. B.QiaoH.ShengZ. H.Snapin-regulated late endosomal transport is critical for efficient autophagy-lysosomal function in neurons201068173862-s2.0-7795732561810.1016/j.neuron.2010.09.022MadayS.WallaceK. E.HolzbaurE. L. F.Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons201219644074172-s2.0-8485785853610.1083/jcb.201106120SaftigP.KlumpermanJ.Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function20091096236352-s2.0-6924922750210.1038/nrm2745KorolchukV. I.SaikiS.LichtenbergM.SiddiqiF. H.RobertsE. A.ImarisioS.JahreissL.SarkarS.FutterM.MenziesF. M.O'KaneC. J.DereticV.RubinszteinD. C.Lysosomal positioning coordinates cellular nutrient responses20111344534602-s2.0-7995331659510.1038/ncb2204LeeS.SatoY.NixonR. A.Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy20113121781778302-s2.0-7995766303510.1523/JNEUROSCI.6412-10.2011YangY.FengL. Q.ZhengX. X.Microtubule and kinesin/dynein-dependent, bi-directional transport of autolysosomes in neurites of PC12 cells2011438114711562-s2.0-7995875860110.1016/j.biocel.2011.04.007SasakiS.Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis20117053493592-s2.0-7995552201410.1097/NEN.0b013e3182160690RosenD. R.SiddiqueT.PattersonD.Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis1993362641559622-s2.0-0027164824ChowC. Y.LandersJ. E.BergrenS. K.SappP. C.GrantA. E.JonesJ. M.EverettL.LenkG. M.McKenna-YasekD. M.WeismanL. S.FiglewiczD.BrownR. H.MeislerM. H.Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS200984185882-s2.0-5804919281210.1016/j.ajhg.2008.12.010JohnsonJ. O.MandrioliJ.BenatarM.AbramzonY.Van DeerlinV. M.TrojanowskiJ. Q.GibbsJ. R.BrunettiM.GronkaS.WuuJ.DingJ.McCluskeyL.Martinez-LageM.FalconeD.HernandezD. G.ArepalliS.ChongS.SchymickJ. C.RothsteinJ.LandiF.WangY. D.CalvoA.MoraG.SabatelliM.MonsurròM. R.BattistiniS.SalviF.SpataroR.SolaP.BorgheroG.GalassiG.ScholzS. W.TaylorJ. P.RestagnoG.ChiòA.TraynorB. J.Exome sequencing reveals VCP mutations as a cause of familial ALS20106858578642-s2.0-7864994129710.1016/j.neuron.2010.11.036SkibinskiG.ParkinsonN. J.BrownJ. M.ChakrabartiL.LloydS. L.HummerichH.NielsenJ. E.HodgesJ. R.SpillantiniM. G.ThusgaardT.BrandnerS.BrunA.RossorM. N.GadeA.JohannsenP.SørensenS. A.GydesenS.FisherE. M. C.CollingeJ.Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia20053788068082-s2.0-2304447101110.1038/ng1609FectoF.YanJ.VemulaS. P.LiuE.YangY.ChenW.ZhengJ. G.ShiY.SiddiqueN.ArratH.DonkervoortS.Ajroud-DrissS.SufitR. L.HellerS. L.DengH.-X.SiddiqueT.SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis20116811144014462-s2.0-8085515063910.1001/archneurol.2011.250PulsI.JonnakutyC.LaMonteB. H.HolzbaurE. L. F.TokitoM.MannE.FloeterM. K.BidusK.DraynaD.OhS. J.BrownR. H.LudlowC. L.FischbeckK. H.Mutant dynactin in motor neuron disease20033344554562-s2.0-003738224010.1038/ng1123WeedonM.HastingsR.CaswellR.XieW.PaszkiewiczK.AntoniadiT.WilliamsM.KingC.GreenhalghL.Newbury-EcobR.EllardS.Exome sequencing identifies a DYNC1H1 mutation in a large pedigree with dominant axonal Charcot-Marie-Tooth disease20118923083122-s2.0-7996089300210.1016/j.ajhg.2011.07.002VerhoevenK.De JongheP.CoenK.VerpoortenN.Auer-GrumbachM.KwonJ. M.FitzPatrickD.SchmeddingE.De VriendtE.JacobsA.Van GerwenV.WagnerK.HartungH. P.TimmermanV.Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy20037237227272-s2.0-003737150910.1086/367847HadanoS.HandC. K.OsugaH.YanagisawaY.OtomoA.DevonR. S.MiyamotoN.Showguchi-MiyataJ.OkadaY.SingarajaR.FiglewiczD. A.KwiatkowskiT.HoslerB. A.SagieT.SkaugJ.NasirJ.BrownR. H.SchererS. W.RouleauG. A.HaydenM. R.IkedaJ. E.A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 220012921661732-s2.0-17944362340YangY.HentatiA.DengH. X.DabbaghO.SasakiT.HiranoM.HungW. Y.OuahchiK.YanJ.AzimA. C.ColeN.GasconG.YagmourA.Ben-HamidaM.Pericak-VanceM.HentatiF.SiddiqueT.The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis20012921601652-s2.0-003478550910.1038/ng1001-160HadanoS.OtomoA.KunitaR.Suzuki-UtsunomiyaK.AkatsukaA.KoikeM.AokiM.UchiyamaY.ItoyamaY.IkedaJ. E.Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1-expressing mouse ALS model by disturbing endolysosomal trafficking201053e98052-s2.0-77956274512OtomoA.KunitaR.Suzuki-UtsunomiyaK.IkedaJ. E.HadanoS.Defective relocalization of ALS2/alsin missense mutants to Rac1-induced macropinosomes accounts for loss of their cellular function and leads to disturbed amphisome formation201158557307362-s2.0-7995231700510.1016/j.febslet.2011.01.045NeumannM.SampathuD. M.KwongL. K.TruaxA. C.MicsenyiM. C.ChouT. T.BruceJ.SchuckT.GrossmanM.ClarkC. M.McCluskeyL. F.MillerB. L.MasliahE.MackenzieI. R.FeldmanH.FeidenW.KretzschmarH. A.TrojanowskiJ. Q.LeeV. M. Y.Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis200631457961301332-s2.0-3374963225910.1126/science.1134108MaruyamaH.MorinoH.ItoH.IzumiY.KatoH.WatanabeY.KinoshitaY.KamadaM.NoderaH.SuzukiH.KomureO.MatsuuraS.KobatakeK.MorimotoN.AbeK.SuzukiN.AokiM.KawataA.HiraiT.KatoT.OgasawaraK.HiranoA.TakumiT.KusakaH.HagiwaraK.KajiR.KawakamiH.Mutations of optineurin in amyotrophic lateral sclerosis201046572952232262-s2.0-7795241924610.1038/nature08971DengH.-X.ChenW.HongS.-T.BoycottK. M.GorrieG. H.SiddiqueN.YangY.FectoF.ShiY.ZhaiH.JiangH.HiranoM.RampersaudE.JansenG. H.DonkervoortS.BigioE. H.BrooksB. R.AjroudK.SufitR. L.HainesJ. L.MugnainiE.Pericak-VanceM. A.SiddiqueT.Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia201147773632112152-s2.0-8005258096910.1038/nature10353FectoF.SiddiqueT.UBQLN2/P62 cellular recycling pathways in amyotrophic lateral sclerosis and frontotemporal dementia20124521571622-s2.0-8485586082010.1002/mus.23278RatovitskiT.CorsonL. B.StrainJ.WongP.ClevelandD. W.CulottaV. C.BorcheltD. R.Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds199988145114602-s2.0-003281596510.1093/hmg/8.8.1451ReaumeA. G.ElliottJ. L.HoffmanE. K.KowallN. W.FerranteR. J.SiwekD. F.WilcoxH. M.FloodD. G.BealM. F.BrownR. H.ScottR. W.SniderW. D.Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury199613143472-s2.0-1584439365810.1038/ng0596-43BruijnL. I.HouseweartM. K.KatoS.AndersonK. L.AndersonS. D.OhamaE.ReaumeA. G.ScottR. W.ClevelandD. W.Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD119982815384185118542-s2.0-003254467410.1126/science.281.5384.1851KabutaT.SuzukiY.WadaK.Degradation of amyotrophic lateral sclerosis-linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy and the proteasome20062814130524305332-s2.0-3375008974010.1074/jbc.M603337200GalJ.StrömA. L.KiltyR.ZhangF.ZhuH.p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis20072821511068110772-s2.0-3424967911610.1074/jbc.M608787200GalJ.StrömA. L.KwinterD. M.KiltyR.ZhangJ.ShiP.FuW.WootenM. W.ZhuH.Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism20091114106210732-s2.0-7035013189310.1111/j.1471-4159.2009.06388.xMorimotoN.NagaiM.OhtaY.MiyazakiK.KurataT.MorimotoM.MurakamiT.TakehisaY.IkedaY.KamiyaT.AbeK.Increased autophagy in transgenic mice with a G93A mutant SOD1 gene2007116711121172-s2.0-3454812501010.1016/j.brainres.2007.06.045LiA.ZhangX.LeW.Altered macroautophagy in the spinal cord of SOD1 mutant mice2008432902932-s2.0-41449113885TianF.MorimotoN.LiuW.OhtaY.DeguchiK.MiyazakiK.AbeK.In vivo optical imaging of motor neuron autophagy in a mouse model of amyotrophic lateral sclerosis2011799859922-s2.0-8005235394610.4161/auto.7.9.16012GamerdingerM.KayaA. M.WolfrumU.ClementA. M.BehlC.BAG3 mediates chaperone-based aggresome-targeting and selective autophagy of misfolded proteins20111221491562-s2.0-7955160933210.1038/embor.2010.203HafezparastM.KlockeR.RuhrbergC.MarquardtA.Ahmad-AnnuarA.BowenS.LalliG.WitherdenA. S.HummerichH.NicholsonS.MorganP. J.OozageerR.PriestleyJ. V.AverillS.KingV. R.BallS.PetersJ.TodaT.YamamotoA.HiraokaY.AugustinM.KorthausD.WattlerS.WabnitzP.DickneiteC.LampelS.BoehmeF.PerausG.PoppA.RudeliusM.SchlegelJ.FuchsH.De AngelisM. H.SchiavoG.ShimaD. T.RussA. P.StummG.MartinJ. E.FisherE. M. C.Mutations in dynein link motor neuron degeneration to defects in retrograde transport200330056208088122-s2.0-003773437010.1126/science.1083129IlievaH. S.YamanakaK.MalkmusS.KakinohanaO.YakshT.MarsalaM.ClevelandD. W.Mutant dynein (Loa) triggers proprioceptive axon loss that extends survival only in the SOD1 ALS model with highest motor neuron death20081053412599126042-s2.0-5044910142910.1073/pnas.0805422105ZhangF.StrömA. L.FukadaK.LeeS.HaywardL. J.ZhuH.Interaction between familial Amyotrophic Lateral Sclerosis (ALS)-linked SOD1 mutants and the dynein complex20072822216691166992-s2.0-3444755023810.1074/jbc.M609743200ChowC. Y.ZhangY.DowlingJ. J.JinN.AdamskaM.ShigaK.SzigetiK.ShyM. E.LiJ.ZhangX.LupskiJ. R.WeismanL. S.MeislerM. H.Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J2007448714968722-s2.0-3444713303810.1038/nature05876FergusonC. J.LenkG. M.MeislerM. H.Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P220091824486848782-s2.0-7045016208810.1093/hmg/ddp460WattsG. D. J.WymerJ.KovachM. J.MehtaS. G.MummS.DarvishD.PestronkA.WhyteM. P.KimonisV. E.Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein20043643773812-s2.0-184248384310.1038/ng1332YamanakaK.SasagawaY.OguraT.Recent advances in p97/VCP/Cdc48 cellular functions2012182311301372-s2.0-7996065442710.1016/j.bbamcr.2011.07.001MeyerH.BugM.BremerS.Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system20121421171232-s2.0-8485647483810.1038/ncb2407RitzD.VukM.KirchnerP.BugM.SchützS.HayerA.BremerS.LuskC.BalohR. H.LeeH.GlatterT.GstaigerM.AebersoldR.WeihlC. C.MeyerH.Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations2011139111611232-s2.0-7996112110410.1038/ncb2301JuJ. S.FuentealbaR. A.MillerS. E.JacksonE.Piwnica-WormsD.BalohR. H.WeihlC. C.Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease200918768758882-s2.0-7404912441210.1083/jcb.200908115AraiT.HasegawaM.AkiyamaH.IkedaK.NonakaT.MoriH.MannD.TsuchiyaK.YoshidaM.HashizumeY.OdaT.TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis200635136026112-s2.0-3375071607410.1016/j.bbrc.2006.10.093SreedharanJ.BlairI. P.TripathiV. B.HuX.VanceC.RogeljB.AckerleyS.DurnallJ. C.WilliamsK. L.BurattiE.BaralleF.De BellerocheJ.MitchellJ. D.LeighP. N.Al-ChalabiA.MillerC. C.NicholsonG.ShawC. E.TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis20083195870166816722-s2.0-4114918075310.1126/science.1154584ParkinsonN.InceP. G.SmithM. O.HighleyR.SkibinskiG.AndersenP. M.MorrisonK. E.PallH. S.HardimanO.CollingeJ.ShawP. J.FisherE. M. C.ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)2006676107410772-s2.0-3374900684510.1212/01.wnl.0000231510.89311.8bHenneW. M.BuchkovichN. J.EmrS. D.The ESCRT pathway201121177912-s2.0-7996022541110.1016/j.devcel.2011.05.015LeeJ. A.BeigneuxA.AhmadS. T.YoungS. G.GaoF. B.ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration20071718156115672-s2.0-3454849227110.1016/j.cub.2007.07.029SanchezP.De CarcerG.SandovalI. V.MoscatJ.Diaz-MecoM. T.Localization of atypical protein kinase C isoforms into lysosome- targeted endosomes through interaction with p621998185306930802-s2.0-0031946369MoscatJ.Diaz-MecoM. T.p62 at the crossroads of autophagy, apoptosis, and cancer20091376100110042-s2.0-6644911403310.1016/j.cell.2009.05.023MatsumotoG.WadaK.OkunoM.KurosawaM.NukinaN.Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins20114422792892-s2.0-8245517211710.1016/j.molcel.2011.07.039KomatsuM.IchimuraY.Physiological significance of selective degradation of p62 by autophagy20105847137413782-s2.0-7795049512310.1016/j.febslet.2010.02.017KomatsuM.KurokawaH.WaguriS.TaguchiK.KobayashiA.IchimuraY.SouY. S.UenoI.SakamotoA.TongK. I.KimM.NishitoY.IemuraS. I.NatsumeT.UenoT.KominamiE.MotohashiH.TanakaK.YamamotoM.The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap120101232132232-s2.0-7764926509110.1038/ncb2021Ramesh BabuJ.Lamar SeibenhenerM.PengJ.StromA. L.KemppainenR.CoxN.ZhuH.WootenM. C.Diaz-MecoM. T.MoscatJ.WootenM. W.Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration200810611071202-s2.0-4524910592010.1111/j.1471-4159.2008.05340.xLaurinN.BrownJ. P.MorissetteJ.RaymondV.Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in paget disease of bone2002706158215882-s2.0-003609402610.1086/340731TroakesC.MaekawaS.WijesekeraL.RogeljB.SiklósL.BellC.SmithB.NewhouseS.VanceC.JohnsonL.HortobágyiT.ShatunovA.Al-ChalabiA.LeighN.ShawC. E.KingA.Al-SarrajS.An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive declineNeuropathology. In pressAl-SarrajS.KingA.TroakesC.SmithB.MaekawaS.BodiI.RogeljB.Al-ChalabiA.HortobágyiT.ShawC. E.P62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS201112266917022-s2.0-8235518082610.1007/s00401-011-0911-2KatsunoM.AdachiH.MinamiyamaM.WazaM.TokuiK.BannoH.SuzukiK.OnodaY.TanakaF.DoyuM.SobueG.Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration2006264712106121172-s2.0-3375133978510.1523/JNEUROSCI.3032-06.2006LaMonteB. H.WallaceK. E.HollowayB. A.ShellyS. S.AscañoJ.TokitoM.Van WinkleT.HowlandD. S.HolzbaurE. L. F.Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration20023457157272-s2.0-003719869810.1016/S0896-6273(02)00696-7RavikumarB.Acevedo-ArozenaA.ImarisioS.BergerZ.VacherC.O'KaneC. J.BrownS. D. M.RubinszteinD. C.Dynein mutations impair autophagic clearance of aggregate-prone proteins20053777717762-s2.0-2284443645110.1038/ng1591SpinosaM. R.ProgidaC.De LucaA.ColucciA. M. R.AlifanoP.BucciC.Functional characterization of Rab7 mutant proteins associated with Charcot-Marie-Tooth type 2B disease2008287164016482-s2.0-3954909832910.1523/JNEUROSCI.3677-07.2008JägerS.BucciC.TanidaI.UenoT.KominamiE.SaftigP.EskelinenE. L.Role for Rab7 in maturation of late autophagic vacuoles200411720483748482-s2.0-724425598910.1242/jcs.01370BainsM.ZaegelV.Mize-BergeJ.HeidenreichK. A.IGF-I stimulates Rab7-RILP interaction during neuronal autophagy201148821121172-s2.0-7865068732710.1016/j.neulet.2010.09.018LinM. G.ZhongQ.Interaction between small GTPase Rab7 and PI3KC3 links autophagy and endocytosis a new Rab7 effector protein sheds light on membrane trafficking pathways20112285882-s2.0-7995605701910.4161/sgtp.2.2.15256BasurayS.MukherjeeS.RomeroE.WilsonM. C.Wandinger-NessA.Rab7 mutants associated with charcot-Marie-Tooth disease exhibit enhanced NGF-stimulated signaling20105122-s2.0-7865013013310.1371/journal.pone.0015351e15351CogliL.ProgidaC.LecciR.BramatoR.KrüttgenA.BucciC.CMT2B-associated Rab7 mutants inhibit neurite outgrowth201012044915012-s2.0-7795618437210.1007/s00401-010-0696-8Eymard-PierreE.LescaG.DolletS.SantorelliF. M.Di CapuaM.BertiniE.Boespflug-TanguyO.Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene20027135185272-s2.0-003672405210.1086/342359HadanoS.KunitaR.OtomoA.Suzuki-UtsunomiyaK.IkedaJ. E.Molecular and cellular function of ALS2/alsin: implication of membrane dynamics in neuronal development and degeneration2007512–474842-s2.0-3454742178510.1016/j.neuint.2007.04.010OtomoA.HadanoS.OkadaT.MizumuraH.KunitaR.NishijimaH.Showguchi-MiyataJ.YanagisawaY.KohikiE.SugaE.YasudaM.OsugaH.NishimotoT.NarumiyaS.IkedaJ. E.ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics20031214167116872-s2.0-004130808210.1093/hmg/ddg184ToppJ. D.GrayN. W.GerardR. D.HorazdovskyB. F.Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor20042792324612246232-s2.0-264253620210.1074/jbc.M313504200KunitaR.OtomoA.MizumuraH.SuzukiK.Showguchi-MiyataJ.YanagisawaY.HadanoS.IkedaJ. E.Homo-oligomerization of ALS2 through its unique carboxyl-terminal regions is essential for the ALS2-associated Rab5 guanine nucleotide exchange activity and its regulatory function on endosome trafficking20042793738626386352-s2.0-464424743010.1074/jbc.M406120200KunitaR.OtomoA.MizumuraH.Suzuki-UtsunomiyaK.HadanoS.IkedaJ. E.The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-activated endocytosis20072822216599166112-s2.0-3444753177510.1074/jbc.M610682200OtomoA.KunitaR.Suzuki-UtsunomiyaK.MizumuraH.OnoeK.OsugaH.HadanoS.IkedaJ. E.ALS2/alsin deficiency in neurons leads to mild defects in macropinocytosis and axonal growth2008370187922-s2.0-4184914190410.1016/j.bbrc.2008.01.177JacquierA.BuhlerE.SchäferM. K. E.BohlD.BlanchardS.BeclinC.HaaseG.Alsin/Rac1 signaling controls survival and growth of spinal motoneurons20066011051172-s2.0-3374571445910.1002/ana.20886CaiH.LinX.XieC.LairdF. M.LaiC.WenH.ChiangH. C.ShimH.FarahM. H.HokeA.PriceD. L.WongP. C.Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress20052533756775742-s2.0-2384444865210.1523/JNEUROSCI.1645-05.2005TaylorR. C.Acquaah-MensahG.SinghalM.MalhotraD.BiswalS.Network inference algorithms elucidate Nrf2 regulation of mouse lung oxidative stress2008482-s2.0-5094911752710.1371/journal.pcbi.1000166e1000166LiQ.SpencerN. Y.PantazisN. J.EngelhardtJ. F.Alsin and SOD1 (G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity20112864640151401622-s2.0-8115515430010.1074/jbc.M111.279711CarterB. J.AnklesariaP.ChoiS.EngelhardtJ. F.Redox modifier genes and pathways in amyotrophic lateral sclerosis2009117156915862-s2.0-6674910205910.1089/ars.2008.2414HadanoS.BennS. C.KakutaS.OtomoA.SudoK.KunitaR.Suzuki-UtsunomiyaK.MizumuraH.ShefnerJ. M.CoxG. A.IwakuraY.BrownR. H.IkedaJ. E.Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking20061522332502-s2.0-3114444870410.1093/hmg/ddi440YouleR. J.NarendraD. P.Mechanisms of mitophagy20111219142-s2.0-7865046797410.1038/nrm3028RavikumarB.ImarisioS.SarkarS.O'KaneC. J.RubinszteinD. C.Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease200812110164916602-s2.0-4624912749010.1242/jcs.025726SarkarS.KrishnaG.ImarisioS.SaikiS.O'KaneC. J.RubinszteinD. C.A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin20081721701782-s2.0-3784904253610.1093/hmg/ddm294FlemingA.NodaT.YoshimoriT.RubinszteinD. C.Chemical modulators of autophagy as biological probes and potential therapeutics2011719172-s2.0-7865044875410.1038/nchembio.500FornaiF.LongoneP.CafaroL.KastsiuchenkaO.FerrucciM.MancaM. L.LazzeriG.SpalloniA.BellioN.LenziP.ModugnoN.SicilianoG.IsidoroC.MurriL.RuggieriS.PaparelliA.Lithium delays progression of amyotrophic lateral sclerosis20081056205220572-s2.0-4114912440610.1073/pnas.0708022105ZhangX.LiL.ChenS.YangD.WangY.ZhangX.WangZ.LeW.Rapamycin treatment augments motor neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis2011744124252-s2.0-7995364710510.4161/auto.7.4.14541